• Tisagenlecleucel demonstrated safety and efficacy in primary CNS lymphoma.

  • CAR-T cells were noted to expand and traffic to the CNS in the absence of systemic disease.

CD19-directed chimerical antigen receptor T-cell (CAR-T) products have gained US Food and Drug Administration approval for systemic large B-cell lymphoma. Because of concerns about potential immune cell-associated neurotoxicity syndrome (ICANS), patients with primary central nervous system (CNS) lymphoma (PCNSL) were excluded from all pivotal CAR-T studies. We conducted a phase 1/2 clinical trial of tisagenlecleucel in a highly refractory patients with PCNSL and significant unmet medical need. Here, we present results of 12 relapsed patients with PCNSL who were treated with tisagenlecleucel and followed for a median time of 12.2 months (range, 3.64-23.5). Grade 1 cytokine release syndrome was observed in 7/12 patients (58.3%), low-grade ICANS in 5/12 (41.6%) patients, and only 1 patient experienced grade 3 ICANS. Seven of 12 patients (58.3%) demonstrated response, including a complete response in 6/12 patients (50%). There were no treatment-related deaths. Three patients had ongoing complete remission at data cutoff. Tisagenlecleucel expanded in the peripheral blood and trafficked to the CNS. Exploratory analysis identified T-cell, CAR T, and macrophage gene signatures in cerebrospinal fluid following infusion when compared with baseline. Overall, tisagenlecleucel was well tolerated and resulted in a sustained remission in 3/7 (42.9%) of initial responders. These data suggest that tisagenlecleucel is safe and effective in this highly refractory patient population. This trial was registered at www.clinicaltrials.gov as #NCT02445248.

1.
Neelapu
SS
,
Locke
FL
,
Bartlett
NL
, et al
.
Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma
.
N Engl J Med.
2017
;
377
(
26
):
2531
-
2544
.
2.
Schuster
SJ
,
Bishop
MR
,
Tam
CS
, et al;
JULIET Investigators
.
Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma
.
N Engl J Med.
2019
;
380
(
1
):
45
-
56
.
3.
Abramson
JS
,
Palomba
ML
,
Gordon
LI
, et al
.
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study
.
Lancet.
2020
;
396
(
10254
):
839
-
852
.
4.
Batchelor
TT
,
DeAngelis
LM
. Lymphoma and Leukemia of the Nervous System, 2nd ed.
New York, NY
:
Springer
;
2013
.
5.
Green
K
,
Hogg
JP
. Central Nervous System Lymphoma.
Treasure Island, FL
:
StatPearls
;
2021
.
6.
Kasenda
B
,
Ferreri
AJ
,
Marturano
E
, et al
.
First-line treatment and outcome of elderly patients with primary central nervous system lymphoma (PCNSL) – a systematic review and individual patient data meta-analysis
.
Ann Oncol.
2015
;
26
(
7
):
1305
-
1313
.
7.
Panageas
KS
,
Elkin
EB
,
Ben-Porat
L
,
Deangelis
LM
,
Abrey
LE
.
Patterns of treatment in older adults with primary central nervous system lymphoma
.
Cancer.
2007
;
110
(
6
):
1338
-
1344
.
8.
Jahnke
K
,
Thiel
E
,
Martus
P
, et al;
German Primary Central Nervous System Lymphoma Study Group
.
Relapse of primary central nervous system lymphoma: clinical features, outcome and prognostic factors
.
J Neurooncol.
2006
;
80
(
2
):
159
-
165
.
9.
Shibamoto
Y
,
Ogino
H
,
Suzuki
G
, et al
.
Primary central nervous system lymphoma in Japan: changes in clinical features, treatment, and prognosis during 1985-2004
.
Neuro-oncol.
2008
;
10
(
4
):
560
-
568
.
10.
Han
CH
,
Batchelor
TT
.
Diagnosis and management of primary central nervous system lymphoma
.
Cancer.
2017
;
123
(
22
):
4314
-
4324
.
11.
Ferreri
AJM
.
Therapy of primary CNS lymphoma: role of intensity, radiation, and novel agents
.
Hematology Am Soc Hematol Educ Program.
2017
;
2017
:
565
-
577
.
12.
Alcantara
M
,
Houillier
C
,
Blonski
M
, et al
.
CAR-T cell therapy in primary central nervous system lymphoma (PCNSL): the clinical experience of the French LOC network
.
Blood.
2022
;
139
(
5
):
792
-
796
.
13.
Siddiqi
T
,
Wang
X
,
Blanchard
MS
, et al
.
CD19-directed CAR T-cell therapy for treatment of primary CNS lymphoma
.
Blood Adv.
2021
;
5
(
20
):
4059
-
4063
.
14.
Pasquini
MC
,
Hu
ZH
,
Curran
K
, et al
.
Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma [published correction appears in Blood Adv. 2021;5(4):1136]
.
Blood Adv.
2020
;
4
(
21
):
5414
-
5424
.
15.
Frigault
MJ
,
Dietrich
J
,
Martinez-Lage
M
, et al
.
Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma
.
Blood.
2019
;
134
(
11
):
860
-
866
.
16.
Fraietta
JA
,
Beckwith
KA
,
Patel
PR
, et al
.
Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia
.
Blood.
2016
;
127
(
9
):
1117
-
1127
.
17.
Long
M
,
Beckwith
K
,
Do
P
, et al
.
Ibrutinib treatment improves T cell number and function in CLL patients
.
J Clin Invest.
2017
;
127
(
8
):
3052
-
3064
.
18.
Lee
DW
,
Santomasso
BD
,
Locke
FL
, et al
.
ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells
.
Biol Blood Marrow Transplant.
2019
;
25
(
4
):
625
-
638
.
19.
Locke
FL
,
Neelapu
SS
,
Bartlett
NL
, et al
.
Preliminary results of prophylactic tocilizumab after axicabtageneciloleucel (axi-cel; KTE-C19) treatment for patients with refractory, aggressive non-Hodgkin lymphoma (NHL)
.
Blood.
2017
;
130
(
suppl 1
):
1547
.
20.
Shibamoto
Y
,
Hayabuchi
N
,
Hiratsuka
J
, et al
.
Is whole-brain irradiation necessary for primary central nervous system lymphoma? Patterns of recurrence after partial-brain irradiation
.
Cancer.
2003
;
97
(
1
):
128
-
133
.
21.
DeFilipp
Z
,
Li
S
,
El-Jawahri
A
, et al
.
High-dose chemotherapy with thiotepa, busulfan, and cyclophosphamide and autologous stem cell transplantation for patients with primary central nervous system lymphoma in first complete remission
.
Cancer.
2017
;
123
(
16
):
3073
-
3079
.
22.
Nayak
L
,
Iwamoto
FM
,
LaCasce
A
, et al
.
PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma
.
Blood.
2017
;
129
(
23
):
3071
-
3073
.
23.
Soussain
C
,
Choquet
S
,
Blonski
M
, et al
.
Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: final analysis of the phase II ‘proof-of-concept’ iLOC study by the Lymphoma study association (LYSA) and the French oculo-cerebral lymphoma (LOC) network
.
Eur J Cancer.
2019
;
117
:
121
-
130
.
24.
Hill
BT
,
Roberts
ZJ
,
Xue
A
,
Rossi
JM
,
Smith
MR
.
Rapid tumor regression from PD-1 inhibition after anti-CD19 chimeric antigen receptor T-cell therapy in refractory diffuse large B-cell lymphoma
.
Bone Marrow Transplant.
2020
;
55
(
6
):
1184
-
1187
.
25.
Gauthier
J
,
Hirayama
AV
,
Purushe
J
, et al
.
Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure
.
Blood.
2020
;
135
(
19
):
1650
-
1660
.
26.
Chong
EA
,
Melenhorst
JJ
,
Lacey
SF
, et al
.
PD-1 blockade modulates chimeric antigen receptor (CAR)-modified T cells: refueling the CAR
.
Blood.
2017
;
129
(
8
):
1039
-
1041
.
You do not currently have access to this content.

Sign in via your Institution